The results indicate that whilst PM2-binding can be abrogated by mutation in HDM2, this generally comes at the cost of significantly reduced p53 binding, and hence would be unlikely to occur in cancers where p53 is not frequently inactivated. Here, MDM2 is linked to cancer.